

**Supplementary Table 15.** Comparison between clinicopathologic characteristic of NSCLCs with oncogenic / likely oncogenic *MET* tyrosine kinase domain (TKD) mutations as a *de novo* genomic event to NSCLCs with *MET* exon 14 alterations in cohort #1.

	<b><i>MET</i> TKD mutant NSCLC* (N=13)</b>	<b><i>MET</i> exon 14 altered NSCLC** (N=123)</b>	<b>P</b>
<b>Age</b>			
Median (range)	74.0 (34.0-88.0)	73.0 (43.0-95.0)	0.8
<b>Sex</b>			
Female	8 (61.5%)	76 (61.8%)	1
Male	5 (38.5%)	47 (38.2%)	
<b>Race</b>			
White	13 (100%)	115 (93.5%)	0.6
Asian	0 (0%)	2 (1.5%)	
Other/Unknown	0 (0%)	6 (5.0%)	
<b>Smoking status</b>			
Former Smoker	13 (100%)	63 (51.2%)	<b>0.003</b>
Current Smoker	0 (0%)	8 (6.5%)	
Never Smoker	0 (0%)	52 (42.3%)	
<b>Tobacco Pack-Years</b>			
Median (range)	24.0 (7.0-80.0)	21.5 (2.0-125)	0.7
<b>Histology</b>			
Adenocarcinoma	10 (76.9%)	95 (77.2%)	0.9
Squamous Cell Carcinoma	1 (7.6%)	6 (4.9%)	
Other	2 (15.5%)	22 (17.9%)	
<b>PD-L1 TPS</b>			
<1%	2 (25.0%)	8 (14.5%)	0.7
1-49%	2 (25.0%)	20 (36.4%)	
≥50%	4 (50.0%)	27 (49.1%)	
NA	5	68	
<b>Concurrent <i>MET</i> Amplification</b>			
Yes	1 (7.6%)	12 (9.8%)	0.9
No	12 (92.4%)	111 (90.2%)	
<b>Harmonized TMB z-score</b>			
Median (range)	0.59 <sup>†</sup> (-0.74-3.30)	-0.58 <sup>‡</sup> (-3.64-1.94)	<b>&lt; 0.001</b>

Abbreviations: TMB, tumor mutation burden; TPS, tumor proportion score; NA, not available.

\* *MET* TKD mutant NSCLC from DFCI and MSKCC

\*\* *MET* exon 14 altered NSCLC (N=123) only from DFCI

<sup>†</sup> TMB z-score of 0.59 corresponds to TMB 13.6 mut/Mb on the DFCI OncoPanel platform and TMB 9.9 mut/Mb on the MSK-IMPACT platform.

<sup>‡</sup> TMB z-score of -0.58 corresponds to TMB 6.05 mut/Mb on the DFCI OncoPanel platform.